UC San Diego Health, the region’s only academic medical center, delivers world-class care and translates groundbreaking research into promising new treatments for patients.
Researchers at UC San Diego School of Medicine and Moores Cancer Center at UC San Diego Health describe the first preclinical model of appendiceal cancer that contains all elements of the tumor, allowing previously stymied investigations to proceed.
UC San Diego researchers and others report that more than one-third of the COVID-19 patients who did not receive any treatment experienced complete resolution of symptoms for at least two consecutive days, but then subsequently reported a return of symptoms.
UC San Diego will be one of multiple sites assessing the safety and efficacy of tecovirimat as a potential treatment for human monkeypox. Marketed as TPOXX, tecovirimat is an antiviral currently approved for treatment of human smallpox in adults and children caused by the variola virus.
UC San Diego Health is now offering a new treatment for patients with low-grade upper tract urothelial cancer that could safely avoid removal of the entire kidney, which may prevent the need for dialysis or kidney transplant in the future.
Bacteriophage therapy shows promise for antibiotic-resistant infections, UC San Diego Health researchers and colleagues show.
The new UC San Diego Shiley EyeMobile for Children has started its engine and is driving to schools in San Diego County to serve low-income families in need of eye exams.
San Diego Magazine, October 29
Imperial Valley Weekly, November 2
FOX 5, November 5
Escondido Times-Advocate, November 5
Keep up with all the latest from UC San Diego. Subscribe to the newsletter today.
